Quarterly report pursuant to Section 13 or 15(d)

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)

v3.23.1
SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details)
$ in Thousands
1 Months Ended 3 Months Ended 27 Months Ended
Jul. 27, 2022
USD ($)
Jan. 31, 2021
USD ($)
Feb. 29, 2020
USD ($)
Oct. 31, 2019
USD ($)
agreement
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2021
USD ($)
Collaborations                            
Contingent payments             $ 1,300,000              
Upfront payment received             125,000              
Payment of cost share to collaboration partner             828       $ 2,118      
Revenue recognized               $ 20,000            
Accounts receivable             29,366 40,320         $ 29,366  
Research and development             10,089       15,474      
Intangible asset             14,681 14,949         14,681  
Accounts payable             6,295 22,508         6,295  
Specified Development Events [Member]                            
Collaborations                            
Contingent payments             279,500              
Specified Regulatory Events [Member]                            
Collaborations                            
Contingent payments             263,100              
Specified Product Launch Events [Member]                            
Collaborations                            
Contingent payments             796,000              
Development and regulatory milestones by non-CNS disease products                            
Collaborations                            
Contingent payments             330,000              
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments             100,000              
Development and regulatory milestones by CNS disease products                            
Collaborations                            
Contingent payments             255,000              
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis                            
Collaborations                            
Contingent payments             150,000              
Grifols                            
Collaborations                            
Upfront payment received         $ 30,000                  
Grifols | Research Services                            
Collaborations                            
Revenue recognized             0       300      
Grifols | Delivery of drug supply for commercialization                            
Collaborations                            
Revenue recognized             1,600       0      
Grifols | Commercial milestones                            
Collaborations                            
Contingent payments         $ 297,500                  
Kissei                            
Collaborations                            
Contingent payments           $ 147,000                
Upfront payment received           $ 33,000                
Revenue, remaining performance obligation             33,000           33,000  
Knight | Commercial and license agreements                            
Collaborations                            
Upfront payment received             2,000              
Knight | Maximum | Commercial milestones | Commercial and license agreements                            
Collaborations                            
Contingent payments             20,000              
Forma                            
Collaborations                            
Upfront fee $ 2,000                          
Research and development                 $ 2,000          
Forma | Commercial milestones                            
Collaborations                            
Potential payments 165,500                          
Forma | Development and regulatory milestones                            
Collaborations                            
Potential payments $ 67,500                          
Forma | Achievement of certain near-term regulatory milestone.                            
Collaborations                            
Research and development               2,500            
fostamatinib                            
Collaborations                            
Revenue recognized             0       0   15,000  
Government contract   $ 16,500                        
Remaining amount of government award expected to be received in succeeding periods             1,500              
fostamatinib | Grifols                            
Collaborations                            
Collaborative payment received     $ 20,000                      
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                            
Collaborations                            
Contingent payments     17,500                      
fostamatinib | Grifols | Creditable advance royalty payment                            
Collaborations                            
Collaborative payment received     $ 2,500                      
fostamatinib | Grifols | Maximum                            
Collaborations                            
Royalty payment as a percentage of net sales         30.00%                  
fostamatinib | Kissei                            
Collaborations                            
Revenue recognized                   $ 5,000        
Deferred revenue                 $ 1,400         $ 1,400
Collaborative payment received                   $ 5,000        
Accounts receivable               20,000            
fostamatinib | Medison | Financing arrangement                            
Collaborations                            
Upfront payment received       $ 5,000                    
Financing liability with accreted interest expense             $ 0 0         0  
Revenue recognized               5,700            
fostamatinib | Medison | Commercial and license agreements                            
Collaborations                            
Upfront payment received       $ 5,000                    
Number of agreements | agreement       2                    
R552                            
Collaborations                            
Company's percentage of development costs             20.00%              
Financing component liability             $ 57,900           57,900  
Financing liability interest accretion discount rate             6.40%              
Financing liability with accreted interest expense             $ 45,400 46,200         45,400  
Accretion expense             0       700      
Development costs due to collaboration partner             15,900           15,900  
Revenue, remaining performance obligation             67,100           67,100  
R552 | Maximum                            
Collaborations                            
Funding commitment             65,000           $ 65,000  
Non-CNS penetrant IP                            
Collaborations                            
Revenue recognized                       $ 60,400    
CNS penetrant IP                            
Collaborations                            
Revenue recognized             0       200      
CNS penetrant IP | Licensed Rights                            
Collaborations                            
Revenue, remaining performance obligation                     6,700      
Royalty | Grifols                            
Collaborations                            
Revenue recognized             700       0      
REZLIDHIA | Forma                            
Collaborations                            
Amortization of intangible assets             300              
Royalty expense             200       $ 0      
REZLIDHIA | Forma | FDA approval and first commercial sale of product                            
Collaborations                            
Intangible asset               15,000            
Accounts payable               $ 15,000            
Payments of milestone payment obligations             $ 15,000